Phosphate binders usage, patients knowledge, and adherence

References

1. ↵
   1. Alkhlaif AA,
   2. Alsuraimi AK,
   3. Bawazir AA

   (2020) Epidemiological profile of end-stage renal diseases in Riyadh, Saudi Arabia. Asian J Med Health 8:16–27.

   OpenUrl
2. 1. Aljabri D

   (2018) Prevalence of chronic kidney disease and it's risk factors in Saudi Adults. JMPR, 2.
3. ↵
   1. Al-Duais M,
   2. Almutairi F,
   3. Shalaby K,
   4. Sakran M

   (2017) Analysis of patients with end-stage renal disease on dialysis in Tabuk City, Saudi Arabia:A single-center, three-year retrospective study. Saudi J Kidney Dis Transpl 28:349.

   OpenUrl
4. ↵
   1. Saudi Center for Organ Transplantation

   Annual Report 2016 Hemodialysis in the Kingdom of Saudi Arabia. Scot.gov.sa, Updated 2018. Cited 2018 November 24, Available from URL: http://www.scot.gov.sa/images/Annual%20Report%20Dialysis%20Chapter%202016.pdf.
5. ↵
   1. Kidney D,
   2. Improving GO,
   3. Work G

   (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1–59.

   OpenUrlPubMed
6. ↵
   1. Wang XR,
   2. Zhang JJ,
   3. Xu XX,
   4. Wu YG

   (2019) Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease:a systematic review and meta-analysis. Ren Fail 41:244–256.

   OpenUrl
7. ↵
   1. Fujii H,
   2. Joki N

   (2017) Mineral metabolism and cardiovascular disease in CKD. Clin Exp Nephrol 21:53–63.

   OpenUrl
8. ↵
   1. AlGhonaim M,
   2. Fathalla A

   (2019) Vascular calcification in patients with chronic kidney disease on dialysis in the Kingdom of Saudi Arabia:a cross-sectional study. Saudi J Kidney Dis Transpl 30:571–580.

   OpenUrl
9. ↵
   1. Al Salmi I,
   2. AlRukhaimi M,
   3. AlSahow A,
   4. Shaheen F,
   5. Al-Ghamdi SG,
   6. AlAli F,
   7. et al.

   (2016) Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council:Initial findings from the dialysis outcomes and practice patterns study (2012-2015). Saudi J Kidney Dis Transpl 27:62–80.

   OpenUrl
10. ↵
    1. Khalil SA

    (2019) Effect of individualized dietary counseling improve hyperphosphatemia among hemodialysis patients. Clin Nutr 38(Supp 1):S230.

    OpenUrl
11. ↵
    1. Khor SM,
    2. Ling Goh AW,
    3. Ping Chong C

    (2020) Evaluation of dietary protein and phosphate intake among the hemodialysis patients with hyperphosphatemia in Penang, Malaysia. Malaysian J Med Res 04:1–8.

    OpenUrl
12. ↵
    1. Sekercioglu N,
    2. Thabane L,
    3. Díaz Martínez JP,
    4. Nesrallah G,
    5. Longo CJ,
    6. et al.

    (2016) Comparative effectiveness of phosphate binders in patients with chronic kidney disease:a systematic review and network meta-analysis. PloS one 11:e0156891.

    OpenUrlCrossRefPubMed
13. ↵
    1. Bravo-Soto GA,
    2. Madrid T

    (2017) Sevelamer versus calcium-based phosphate binders for chronic kidney disease. Medwave 17(Suppl 2):e6942.

    OpenUrl
14. ↵
    1. Mouli PC,
    2. Sneha S,
    3. Balekundri SA,
    4. Shlini P

    (2018) Efficacy of sevelamer hydrochloride and sevelamer carbonate in hyperphosphatemia condition-A review. Asia Jour Rese Chem 11:768–772.

    OpenUrl
15. ↵
    1. Hjemås BJ,
    2. Bøvre K,
    3. Mathiesen L,
    4. Lindstrøm JC,
    5. Bjerknes K

    (2019) Interventional study to improve adherence to phosphate binder treatment in dialysis patients. BMC Nephrol 20:178.

    OpenUrl
16. ↵
    1. AlSahow A,
    2. AlRukhaimi M,
    3. Al Wakeel J,
    4. Al-Ghamdi SM,
    5. AlGhareeb S,
    6. AlAli F,
    7. et al.

    (2016) Demographics and key clinical characteristics of hemodialysis patients from the Gulf Cooperation Council countries enrolled in the dialysis outcomes and practice patterns study phase 5 (2012-2015). Saudi J Kidney Dis Transpl 27:S12–S23.

    OpenUrl
17. ↵
    1. Chao CT,
    2. Huang JW

    (2016) Geriatric syndromes are potential determinants of the medication adherence status in prevalent dialysis patients. Peer J 4:e2122.

    OpenUrl
18. ↵
    1. Shaheen FA,
    2. Al Wakeel J,
    3. Al-Ghamdi SM,
    4. Alhelal B,
    5. AlGhareeb S,
    6. Al Obaidli AA,
    7. et al.

    (2016) Cardiovascular and cerebrovascular comorbidities in hemodialysis patients from the Gulf Cooperation Council countries enrolled in the dialysis outcome and practice pattern study phase 5 (2012-2015). Saudi J Kidney Dis Transpl 27(Suppl 1):S24–S30.

    OpenUrl
19. ↵
    1. Lim E,
    2. Hyun S,
    3. Lee JM,
    4. Kim S,
    5. Lee MJ,
    6. Lee SM,
    7. et al.

    (2018) Effects of education on low-phosphate diet and phosphate binder intake to control serum phosphate among maintenance hemodialysis patients:A randomized controlled trial. Kidney Res Clin Pract 37:69–76.

    OpenUrlPubMed
20. ↵
    1. Green JA,
    2. Cavanaugh KL

    (2015) Understanding the influence of educational attainment on kidney health and opportunities for improved care. Adv Chronic Kidney Dis 22:24–30.

    OpenUrl
21. ↵
    1. Jovanovich A

    (2020) Time to reconsider calcium-based phosphate binders in dialysis?A call for a well-designed randomized controlled trial. Am J Kidney Dis 75:453–455.

    OpenUrl
22. ↵
    1. Chan S,
    2. Au K,
    3. Francis RS,
    4. Mudge DW,
    5. Johnson DW,
    6. Pillans PI

    (2017) Phosphate binders in patients with chronic kidney disease. Aust Prescr 40:10–14.

    OpenUrl
23. ↵
    1. Ando S,
    2. Sakuma M,
    3. Morimoto Y,
    4. Arai H

    (2015) The effect of various boiling conditions on reduction of phosphorus and protein in meat. J Ren Nutr 25:504–509.

    OpenUrl
24. ↵
    1. Barreto FC,
    2. Barreto DV,
    3. Massy ZA,
    4. Drüeke TB

    (2019) Strategies for phosphate control in patients with ckd. Kidney Int Rep 4:1043–1056.

    OpenUrl
25. ↵
    1. Floege J

    (2020) Phosphate binders in chronic kidney disease:an updated narrative review of recent data. J Nephrol 33:497–508.

    OpenUrlPubMed
26. ↵
    1. Fissell RB,
    2. Karaboyas A,
    3. Bieber BA,
    4. Sen A,
    5. Li Y,
    6. Lopes AA,
    7. et al.

    (2016) Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers:Findings from the DOPPS. Hemodial Int 20:38–49.

    OpenUrlCrossRefPubMed
27. 1. Wileman V,
    2. Farrington K,
    3. Wellsted D,
    4. Almond M,
    5. Davenport A,
    6. Chilcot J

    (2015) Medication beliefs are associated with phosphate binder non-adherence in hyperphosphatemic haemodialysis patients. Br J Health Psychol 20:563–578.

    OpenUrl
28. ↵
    1. Arenas Jimenez MD,
    2. Alvarez-Ude Cotera F

    (2016) Strategies to improve adherence to phosphate binder therapy. A challenge to the relationship doctor–patient. Nefrol Engl Ed 36:583–586.

    OpenUrl
29. ↵
    1. Chen NX,
    2. O''Neill KD,
    3. Allen MR,
    4. Newman CL,
    5. Moe SM

    (2015) Low bone turnover in chronic kidney disease is associated with decreased vegf-a expression and osteoblast differentiation. Am J Nephrol 41:464–473.

    OpenUrl
30. ↵
    1. Ghimire S,
    2. Castelino RL,
    3. Lioufas NM,
    4. Peterson GM,
    5. Zaidi STR

    (2015) Non-adherence to medication therapy in haemodialysis patients:a systematic review. PLoS One 10:e0144119.

    OpenUrl
31. ↵
    1. Umeukeje EM,
    2. Mixon AS,
    3. Cavanaugh KL

    (2018) Phosphate-control adherence in hemodialysis patients:current perspectives. Patient Prefer Adherence 12:1175–1191.

    OpenUrl
32. ↵
    1. Ghimire S,
    2. Castelino RL,
    3. Jose MD,
    4. Zaidi STR

    (2017) Medication adherence perspectives in haemodialysis patients:A qualitative study. BMC Nephrol 18:167.

    OpenUrl
33. ↵
    1. Al Salmi I,
    2. Larkina M,
    3. Wang M,
    4. Subramanian L,
    5. Morgenstern H,
    6. Jacobson SH,
    7. et al.

    (2018) Missed hemodialysis treatments:international variation, predictors, and outcomes in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 72:634–643.

    OpenUrl